MX2019008056A - Agonistas del receptor pac1 (maxcaps) y usos de estos. - Google Patents

Agonistas del receptor pac1 (maxcaps) y usos de estos.

Info

Publication number
MX2019008056A
MX2019008056A MX2019008056A MX2019008056A MX2019008056A MX 2019008056 A MX2019008056 A MX 2019008056A MX 2019008056 A MX2019008056 A MX 2019008056A MX 2019008056 A MX2019008056 A MX 2019008056A MX 2019008056 A MX2019008056 A MX 2019008056A
Authority
MX
Mexico
Prior art keywords
amino acid
fragment
sequence
maxadilan
pac1 receptor
Prior art date
Application number
MX2019008056A
Other languages
English (en)
Inventor
R Pisegna Joseph
M Germano Patrizia
P Vu John
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019008056A publication Critical patent/MX2019008056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En determinadas modalidades, se proporcionan agonistas del receptor PAC1 novedosos, en donde los agonistas comprenden una secuencia de direccionamiento que se une al receptor PAC1 y dicha secuencia de direccionamiento se fija a una secuencia de aminoácidos que comprende un fragmento de la secuencia de aminoácidos de maxadilán, en donde la secuencia de direccionamiento comprende un péptido PACAP de 38 aminoácidos de longitud completa o un fragmento N -terminal de este que contiene la secuencia de aminoácidos HSDGIF, en donde dicha secuencia de direccionamiento opcionalmente comprende una inserción de aminoácidos entre los residuos 11 y 12 de dicho péptido PACAP o fragmento de este; y el fragmento de la secuencia de aminoácidos de maxadilán comprende un fragmento de la secuencia de maxadilán eficaz para activar la señalización de PAC1.
MX2019008056A 2017-01-05 2018-01-04 Agonistas del receptor pac1 (maxcaps) y usos de estos. MX2019008056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762442906P 2017-01-05 2017-01-05
PCT/US2018/012405 WO2018129200A2 (en) 2017-01-05 2018-01-04 Pac1 receptor agonists (maxcaps) and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008056A true MX2019008056A (es) 2019-11-21

Family

ID=62791208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008056A MX2019008056A (es) 2017-01-05 2018-01-04 Agonistas del receptor pac1 (maxcaps) y usos de estos.

Country Status (8)

Country Link
US (2) US11186622B2 (es)
EP (1) EP3565573B1 (es)
JP (1) JP7183164B2 (es)
CN (1) CN110300595A (es)
AU (1) AU2018205458A1 (es)
CA (1) CA3049212A1 (es)
MX (1) MX2019008056A (es)
WO (1) WO2018129200A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300595A (zh) 2017-01-05 2019-10-01 加利福尼亚大学董事会 Pac1受体激动剂(maxcap)及其用途
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
CN110747163B (zh) * 2019-11-13 2021-06-11 暨南大学 一种提高人脂肪间充质干细胞成脂分化的方法及其专用培养基
CN111110830B (zh) * 2020-02-18 2023-05-26 暨南大学 生物活性多肽pacap在制备提高肥胖男性生育力的药物中的应用
WO2024140994A1 (zh) * 2022-12-29 2024-07-04 杭州百懿生物药业有限公司 一种融合蛋白

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496542A (en) 1981-03-30 1985-01-29 Usv Pharmaceutical Corporation N-substituted-amido-amino acids
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
CH677886A5 (es) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
CZ2001253A3 (cs) 1998-07-20 2001-11-14 Societe De Conseils De Recherches Et D'application Peptidové analogy PACAP
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
AU2001261423A1 (en) * 2000-05-11 2001-11-20 The General Hospital Corporation Vasodilator-thrombolytic fusion proteins and conjugates
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
JP2005538942A (ja) 2002-05-03 2005-12-22 ニューロノヴァ アーベー 成体の神経幹又は前駆体細胞に関するｐａｃａｐ、ｖｉｐ及びマキサディランの機能的役割及び治療への使用可能性
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
US7928186B2 (en) 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN101125882B (zh) * 2007-07-20 2010-10-13 暨南大学 重组pac1受体激动剂rmmax及其表达方法与应用
AU2009296456B2 (en) 2008-09-25 2016-06-16 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with anticancer agents
CA2779496A1 (en) * 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
AU2011213649A1 (en) 2010-02-05 2012-08-23 The Administrators Of The Tulane Educational Fund The use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mTOR) complexes
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
US20160122406A1 (en) 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN110300595A (zh) 2017-01-05 2019-10-01 加利福尼亚大学董事会 Pac1受体激动剂(maxcap)及其用途

Also Published As

Publication number Publication date
WO2018129200A2 (en) 2018-07-12
WO2018129200A3 (en) 2018-08-09
AU2018205458A1 (en) 2019-07-11
JP2020503367A (ja) 2020-01-30
EP3565573B1 (en) 2023-08-23
EP3565573A4 (en) 2020-08-12
US12049486B2 (en) 2024-07-30
CN110300595A (zh) 2019-10-01
US20190322718A1 (en) 2019-10-24
JP7183164B2 (ja) 2022-12-05
EP3565573A2 (en) 2019-11-13
US11186622B2 (en) 2021-11-30
US20220251162A1 (en) 2022-08-11
CA3049212A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2019008056A (es) Agonistas del receptor pac1 (maxcaps) y usos de estos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
NZ740644A (en) Glucagon receptor agonists
MX2017016101A (es) Polinucleotidos y polipetidos de adenovirus.
MX2009006564A (es) Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EA201792245A1 (ru) Биоконъюгаты и их применения
RU2021134101A (ru) Модифицированная j-цепь
MX2010012695A (es) Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2021002295A (es) Variantes de proteinas recombinantes.
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
NZ609216A (en) Anticancer fusion protein
ZA202001167B (en) Glucagon-like peptide 1 receptor agonists and uses thereof
NZ706884A (en) Fc gamma receptor iib variants
MY194819A (en) Bone-targeting antibodies
MY195726A (en) Steviol Glycoside Transport
MY187334A (en) Xylanase
MX2020005670A (es) Variantes de expresión de cdkl5 y proteínas de fusión de cdkl5.
WO2017060318A3 (en) Kaurenoic acid hydroxylases
MX2017008505A (es) Composicion.
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.